uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q2.1956 | Q2 | What is the allele frequency of the SNP rs77168471 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs77168471 has an effect allele G frequency of 0.0354 and non-effect allele A frequency of 0.9646. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs77168471"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_7642436', 'SNP': 'rs77168471', 'effect_allele': 'G', 'effect_allele_frequency': 0.0353999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9646000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.1657 | Q2 | What is the allele frequency of the SNP rs115014884 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs115014884 has an effect allele T frequency of 0.0117 and non-effect allele C frequency of 0.9883. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs115014884"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6444116', 'SNP': 'rs115014884', 'effect_allele': 'T', 'effect_allele_frequency': 0.0117, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9883}] | general | Calculate, Select | Allele Frequency |
Q2.613 | Q2 | What is the allele frequency of the SNP rs16922090 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs16922090 has an effect allele G frequency of 0.0909 and non-effect allele A frequency of 0.9091. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs16922090"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_2303002', 'SNP': 'rs16922090', 'effect_allele': 'G', 'effect_allele_frequency': 0.0908999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9091000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.183 | Q2 | What is the allele frequency of the SNP rs10489980 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs10489980 has an effect allele C frequency of 0.3913 and non-effect allele G frequency of 0.6087. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs10489980"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_707870', 'SNP': 'rs10489980', 'effect_allele': 'C', 'effect_allele_frequency': 0.3913, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.6087}] | general | Calculate, Select | Allele Frequency |
Q2.305 | Q2 | What is the allele frequency of the SNP rs2124969 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs2124969 has an effect allele C frequency of 0.3890 and non-effect allele T frequency of 0.6110. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs2124969"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_1126628', 'SNP': 'rs2124969', 'effect_allele': 'C', 'effect_allele_frequency': 0.389, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.611}] | general | Calculate, Select | Allele Frequency |
Q2.502 | Q2 | What is the allele frequency of the SNP rs60027946 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs60027946 has an effect allele G frequency of 0.3973 and non-effect allele T frequency of 0.6027. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs60027946"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_1796359', 'SNP': 'rs60027946', 'effect_allele': 'G', 'effect_allele_frequency': 0.3973, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.6027}] | general | Calculate, Select | Allele Frequency |
Q2.1696 | Q2 | What is the allele frequency of the SNP rs6805627 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs6805627 has an effect allele C frequency of 0.1357 and non-effect allele G frequency of 0.8643. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs6805627"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6652410', 'SNP': 'rs6805627', 'effect_allele': 'C', 'effect_allele_frequency': 0.1357, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.8643000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.1721 | Q2 | What is the allele frequency of the SNP rs2003343 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs2003343 has an effect allele A frequency of 0.0099 and non-effect allele G frequency of 0.9901. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs2003343"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6715733', 'SNP': 'rs2003343', 'effect_allele': 'A', 'effect_allele_frequency': 0.0099, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9901}] | general | Calculate, Select | Allele Frequency |
Q2.1662 | Q2 | What is the allele frequency of the SNP rs34961808 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs34961808 has an effect allele A frequency of 0.0788 and non-effect allele T frequency of 0.9212. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs34961808"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6462699', 'SNP': 'rs34961808', 'effect_allele': 'A', 'effect_allele_frequency': 0.0788, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9212}] | general | Calculate, Select | Allele Frequency |
Q2.1639 | Q2 | What is the allele frequency of the SNP rs41279908 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs41279908 has an effect allele A frequency of 0.1148 and non-effect allele G frequency of 0.8852. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs41279908"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6366179', 'SNP': 'rs41279908', 'effect_allele': 'A', 'effect_allele_frequency': 0.1148, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.8852}] | general | Calculate, Select | Allele Frequency |
Q2.523 | Q2 | What is the allele frequency of the SNP rs7799403 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs7799403 has an effect allele G frequency of 0.3564 and non-effect allele C frequency of 0.6436. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs7799403"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_1887270', 'SNP': 'rs7799403', 'effect_allele': 'G', 'effect_allele_frequency': 0.3564, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.6436}] | general | Calculate, Select | Allele Frequency |
Q2.1985 | Q2 | What is the allele frequency of the SNP rs4424040 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs4424040 has an effect allele G frequency of 0.0477 and non-effect allele A frequency of 0.9523. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs4424040"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_7723605', 'SNP': 'rs4424040', 'effect_allele': 'G', 'effect_allele_frequency': 0.0476999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9523000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.1078 | Q2 | What is the allele frequency of the SNP rs1554009 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs1554009 has an effect allele G frequency of 0.3380 and non-effect allele A frequency of 0.6620. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs1554009"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_4157542', 'SNP': 'rs1554009', 'effect_allele': 'G', 'effect_allele_frequency': 0.3379999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.6620000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.482 | Q2 | What is the allele frequency of the SNP rs41529545 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs41529545 has an effect allele C frequency of 0.0424 and non-effect allele A frequency of 0.9576. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs41529545"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_1709708', 'SNP': 'rs41529545', 'effect_allele': 'C', 'effect_allele_frequency': 0.0423999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9576000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.160 | Q2 | What is the allele frequency of the SNP rs6976083 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs6976083 has an effect allele T frequency of 0.3444 and non-effect allele G frequency of 0.6556. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs6976083"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_598856', 'SNP': 'rs6976083', 'effect_allele': 'T', 'effect_allele_frequency': 0.3444, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.6556}] | general | Calculate, Select | Allele Frequency |
Q2.1253 | Q2 | What is the allele frequency of the SNP rs12466041 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs12466041 has an effect allele T frequency of 0.0408 and non-effect allele C frequency of 0.9592. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs12466041"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_4892800', 'SNP': 'rs12466041', 'effect_allele': 'T', 'effect_allele_frequency': 0.0408, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9592}] | general | Calculate, Select | Allele Frequency |
Q2.1205 | Q2 | What is the allele frequency of the SNP rs12671012 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs12671012 has an effect allele A frequency of 0.0661 and non-effect allele G frequency of 0.9339. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs12671012"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_4694579', 'SNP': 'rs12671012', 'effect_allele': 'A', 'effect_allele_frequency': 0.0661, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9339}] | general | Calculate, Select | Allele Frequency |
Q2.17 | Q2 | What is the allele frequency of the SNP rs7330113 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs7330113 has an effect allele A frequency of 0.1762 and non-effect allele G frequency of 0.8238. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs7330113"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_62844', 'SNP': 'rs7330113', 'effect_allele': 'A', 'effect_allele_frequency': 0.1762, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.8238}] | general | Calculate, Select | Allele Frequency |
Q2.1550 | Q2 | What is the allele frequency of the SNP rs2322964 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs2322964 has an effect allele C frequency of 0.3625 and non-effect allele G frequency of 0.6375. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs2322964"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_5963326', 'SNP': 'rs2322964', 'effect_allele': 'C', 'effect_allele_frequency': 0.3625, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.6375}] | general | Calculate, Select | Allele Frequency |
Q2.1081 | Q2 | What is the allele frequency of the SNP rs7572368 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs7572368 has an effect allele C frequency of 0.1335 and non-effect allele A frequency of 0.8665. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs7572368"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_4167672', 'SNP': 'rs7572368', 'effect_allele': 'C', 'effect_allele_frequency': 0.1334999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.8665}] | general | Calculate, Select | Allele Frequency |
Q2.1972 | Q2 | What is the allele frequency of the SNP rs60276348 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs60276348 has an effect allele T frequency of 0.1487 and non-effect allele C frequency of 0.8513. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs60276348"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_7694955', 'SNP': 'rs60276348', 'effect_allele': 'T', 'effect_allele_frequency': 0.1487, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.8513}] | general | Calculate, Select | Allele Frequency |
Q2.552 | Q2 | What is the allele frequency of the SNP rs12148129 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs12148129 has an effect allele G frequency of 0.0460 and non-effect allele T frequency of 0.9540. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs12148129"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_2011908', 'SNP': 'rs12148129', 'effect_allele': 'G', 'effect_allele_frequency': 0.046, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.954}] | general | Calculate, Select | Allele Frequency |
Q2.1554 | Q2 | What is the allele frequency of the SNP rs7894799 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs7894799 has an effect allele C frequency of 0.4678 and non-effect allele T frequency of 0.5322. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs7894799"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_5987165', 'SNP': 'rs7894799', 'effect_allele': 'C', 'effect_allele_frequency': 0.4678, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.5322}] | general | Calculate, Select | Allele Frequency |
Q2.665 | Q2 | What is the allele frequency of the SNP rs35447393 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs35447393 has an effect allele A frequency of 0.0210 and non-effect allele C frequency of 0.9790. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs35447393"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_2533259', 'SNP': 'rs35447393', 'effect_allele': 'A', 'effect_allele_frequency': 0.021, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.979}] | general | Calculate, Select | Allele Frequency |
Q2.1626 | Q2 | What is the allele frequency of the SNP rs11939851 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs11939851 has an effect allele A frequency of 0.2186 and non-effect allele G frequency of 0.7814. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs11939851"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_6333390', 'SNP': 'rs11939851', 'effect_allele': 'A', 'effect_allele_frequency': 0.2186, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.7814}] | general | Calculate, Select | Allele Frequency |
Q2.1028 | Q2 | What is the allele frequency of the SNP rs149668 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs149668 has an effect allele A frequency of 0.0177 and non-effect allele G frequency of 0.9823. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs149668"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_3999308', 'SNP': 'rs149668', 'effect_allele': 'A', 'effect_allele_frequency': 0.0177, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9823}] | general | Calculate, Select | Allele Frequency |
Q2.1994 | Q2 | What is the allele frequency of the SNP rs146706990 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs146706990 has an effect allele A frequency of 0.0293 and non-effect allele C frequency of 0.9707. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs146706990"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_7745045', 'SNP': 'rs146706990', 'effect_allele': 'A', 'effect_allele_frequency': 0.0293, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9707}] | general | Calculate, Select | Allele Frequency |
Q2.1519 | Q2 | What is the allele frequency of the SNP rs4730978 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs4730978 has an effect allele A frequency of 0.1974 and non-effect allele G frequency of 0.8026. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs4730978"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_5860339', 'SNP': 'rs4730978', 'effect_allele': 'A', 'effect_allele_frequency': 0.1974, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.8026}] | general | Calculate, Select | Allele Frequency |
Q2.968 | Q2 | What is the allele frequency of the SNP rs201393564 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs201393564 has an effect allele T frequency of 0.0376 and non-effect allele C frequency of 0.9624. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs201393564"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_3713564', 'SNP': 'rs201393564', 'effect_allele': 'T', 'effect_allele_frequency': 0.0376, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9624}] | general | Calculate, Select | Allele Frequency |
Q2.1883 | Q2 | What is the allele frequency of the SNP rs9931725 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs9931725 has an effect allele C frequency of 0.1918 and non-effect allele T frequency of 0.8082. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs9931725"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_7321295', 'SNP': 'rs9931725', 'effect_allele': 'C', 'effect_allele_frequency': 0.1917999999999999, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.8082000000000001}] | general | Calculate, Select | Allele Frequency |
Q2.287 | Q2 | What is the allele frequency of the SNP rs2569094 in a Parkinson's Disease study involving a European cohort? | According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs2569094 has an effect allele T frequency of 0.4959 and non-effect allele C frequency of 0.5041. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.ParkinsonDisease_CompleteGeneData_No23andMe`
WHERE SNP = "rs2569094"
LIMIT 100 | [{'UUID': 'PDno23andme_full_gene_notext_1083575', 'SNP': 'rs2569094', 'effect_allele': 'T', 'effect_allele_frequency': 0.4959, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.5041}] | general | Calculate, Select | Allele Frequency |
Q22.161 | Q22 | What is Amrix? | Amrix, also known generically as Cyclobenzaprine Hydrochloride, was approved by the FDA in 1977 to treat Spasticity, Myalgia, Muscle spasm, spinal cord disease, and cerebral palsy. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_5142', 'tradeNames_string': 'Amrix, Cyclobenzaprine hydrochloride, Flexeril', 'drugName': 'Cyclobenzaprine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string... | general | Similarity Search, Select | Metadata |
Q22.506 | Q22 | What is Signifor Lar Kit? | Signifor Lar Kit, also known generically as Pasireotide Pamoate, was approved by the FDA in 2014 to treat acromegaly. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_6120', 'tradeNames_string': 'Signifor lar, Signifor lar kit', 'drugName': 'Pasireotide Pamoate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Somatostatin receptor 3 agonist', 'linkedDiseasesDrug_string': 'Acromegaly (EFO_1001485)', 'newLinkedTarge... | general | Similarity Search, Select | Metadata |
Q22.402 | Q22 | What is Qmiiz Odt? | Qmiiz Odt, also known generically as Meloxicam, was approved by the FDA in 2000 to treat rheumatoid arthritis, juvenile idiopathic arthritis, rheumatic disease, and osteoarthritis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_988', 'tradeNames_string': 'Anjeso, Meloxicam, Mobic, Qmiiz odt, Vivlodex', 'drugName': 'Meloxicam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase-2 inhibitor', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Rheumatic... | general | Similarity Search, Select | Metadata |
Q22.158 | Q22 | What is Eucrisa? | Eucrisa, also known generically as Crisaborole, was approved by the FDA in 2016 to treat Eczema and atopic eczema. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_5927', 'tradeNames_string': 'Eucrisa', 'drugName': 'Crisaborole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 4 inhibitor', 'linkedDiseasesDrug_string': 'Eczema (HP_0000964), Psoriasis (EFO_0000676), Localised Scleroderm... | general | Similarity Search, Select | Metadata |
Q22.326 | Q22 | What is Nourianz? | Nourianz, also known generically as Istradefylline, was approved by the FDA in 2019 to treat Parkinson disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2983', 'tradeNames_string': 'Nourianz', 'drugName': 'Istradefylline', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Adenosine A2a receptor antagonist', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180), Liver Disease (EFO_000... | general | Similarity Search, Select | Metadata |
Q22.216 | Q22 | What is Promacta Kit? | Promacta Kit, also known generically as Eltrombopag Olamine, was approved by the FDA in 2008 to treat Thrombocytopenia, chronic hepatitis C virus infection, severe aplastic anemia, and autoimmune thrombocytopenic purpura. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2769', 'tradeNames_string': 'Promacta, Promacta kit', 'drugName': 'Eltrombopag Olamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thrombopoietin receptor agonist', 'linkedDiseasesDrug_string': 'Thrombocytopenia (HP_0001873), Autoimmune T... | general | Similarity Search, Select | Metadata |
Q22.238 | Q22 | What is Imvexxy? | Imvexxy, also known generically as Estradiol, was approved by the FDA in 1975 to treat Premature ovarian insufficiency, Dyspareunia, and hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_6277', 'tradeNames_string': 'Adgyn estro, Alora, Aquagen, Bedol, Climara, Climara Pro, Dermestril 100, Dermestril 25, Dermestril 50, Dermestril septem 25, Dermestril septem 50, Dermestril septem 75, Divigel, E-Cypionate, Elestrim, Elestrin, Elleste solo, Elleste solo mx 40, Elleste solo mx... | general | Similarity Search, Select | Metadata |
Q22.293 | Q22 | What is Vyondys 53? | Vyondys 53, also known generically as Golodirsen, was approved by the FDA in 2019 to treat Duchenne muscular dystrophy and muscular dystrophy. It is a oligonucleotide therapy that acts as a(n) positive modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_4074', 'tradeNames_string': 'Vyondys 53', 'drugName': 'Golodirsen', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'positive modulator', 'drugMechanismOfAction': 'Dystrophin pre-mRNA positive modulator', 'linkedDiseasesDrug_string': 'Muscular Dystrophy (MONDO_0020121), Duchenne ... | general | Similarity Search, Select | Metadata |
Q22.304 | Q22 | What is Hysingla Er? | Hysingla Er, also known generically as Hydrocodone Bitartrate, was approved by the FDA in 1943 to treat pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2476', 'tradeNames_string': 'Dicodid, Hysingla, Hysingla er, Mercodinone, Vantrela er, Zohydro er', 'drugName': 'Hydrocodone Bitartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta agonist', 'linkedDiseases... | general | Similarity Search, Select | Metadata |
Q22.362 | Q22 | What is Liletta? | Liletta, also known generically as Levonorgestrel, was approved by the FDA in 1982 to treat Menorrhagia. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2857', 'tradeNames_string': 'Athentia next, Emerres, Emerres una, Ezinelle, Fallback solo, Her style, Isteranda, Jadelle, Jaydess, Kyleena, Levonelle, Levonelle one step, Levonelle-2, Levonorgestrel, Levosert, Liletta, Microval, Mirena, Norgeston, Norplant, Norplant Ii, Norplant System, Op... | general | Similarity Search, Select | Metadata |
Q22.679 | Q22 | What is Caprelsa? | Caprelsa, also known generically as Vandetanib, was approved by the FDA in 2011 to treat cancer, neoplasm, papillary thyroid carcinoma, thyroid carcinoma, thyroid neoplasm, thyroid cancer, and medullary thyroid gland carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_1931', 'tradeNames_string': 'Caprelsa, Zactima', 'drugName': 'Vandetanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Ephrin receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papil... | general | Similarity Search, Select | Metadata |
Q22.334 | Q22 | What is Acuvail? | Acuvail, also known generically as Ketorolac Tromethamine, was approved by the FDA in 1989 to treat Ocular pain, inflammation, pain, and cataract. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2258', 'tradeNames_string': 'Acular, Acular ls, Acular preservative free, Acuvail, Ketorolac tromethamine, Sprix, Toradol', 'drugName': 'Ketorolac Tromethamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'link... | general | Similarity Search, Select | Metadata |
Q22.202 | Q22 | What is Silenor? | Silenor, also known generically as Doxepin Hydrochloride, was approved by the FDA in 1969 to treat atopic eczema, bipolar disorder, unipolar depression, insomnia, and alcohol dependence. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2495', 'tradeNames_string': 'Adapin, Doxepin hydrochloride, Quitaxon, Silenor, Sinequan, Xepin, Zonalon', 'drugName': 'Doxepin Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDisea... | general | Similarity Search, Select | Metadata |
Q22.80 | Q22 | What is Nexletol? | Nexletol, also known generically as Bempedoic Acid, was approved by the FDA in 2020 to treat cardiovascular disease, coronary artery disease, atherosclerosis, and familial hypercholesterolemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_5953', 'tradeNames_string': 'Nexletol', 'drugName': 'Bempedoic Acid', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'ATP-citrate synthase inhibitor', 'linkedDiseasesDrug_string': 'Hyperlipidemia (MONDO_0021187), Coronary Artery Disease (EFO_... | general | Similarity Search, Select | Metadata |
Q22.605 | Q22 | What is Tadliq? | Tadliq, also known generically as Tadalafil, was approved by the FDA in 2003 to treat Impotence, benign prostatic hyperplasia, pulmonary arterial hypertension, erectile dysfunction, and pulmonary hypertension. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_1194', 'tradeNames_string': 'Adcirca, Cialis, Tadliq', 'drugName': 'Tadalafil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 5A inhibitor', 'linkedDiseasesDrug_string': 'Eisenmenger Syndrome (EFO_0009200), Erectile Dysfun... | general | Similarity Search, Select | Metadata |
Q22.576 | Q22 | What is Koselugo? | Koselugo, also known generically as Selumetinib Sulfate, was approved by the FDA in 2020 to treat neurofibromatosis and neurofibromatosis type 1. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_3990', 'tradeNames_string': 'Koselugo', 'drugName': 'Selumetinib Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor', 'linkedDiseasesDrug_string': 'Pancreatic C... | general | Similarity Search, Select | Metadata |
Q22.452 | Q22 | What is Nerlynx? | Nerlynx, also known generically as Neratinib Maleate, was approved by the FDA in 2017 to treat breast carcinoma and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_6198', 'tradeNames_string': 'Nerlynx', 'drugName': 'Neratinib Maleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-4 inhibitor', 'linkedDiseasesDrug_string': 'Breast Carcinoma (EFO_0000305), Breast C... | general | Similarity Search, Select | Metadata |
Q22.513 | Q22 | What is Alimta? | Alimta, also known generically as Pemetrexed, was approved by the FDA in 2004 to treat cancer, mesothelioma, neoplasm, malignant pleural mesothelioma, and malignant peritoneal mesothelioma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_4615', 'tradeNames_string': 'Alimta, Pemfexy', 'drugName': 'Pemetrexed', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dihydrofolate reductase inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992)... | general | Similarity Search, Select | Metadata |
Q22.633 | Q22 | What is Xyosted (Autoinjector)? | Xyosted (Autoinjector), also known generically as Testosterone Enanthate, was approved by the FDA in 1953 to treat Hypogonadotropic hypogonadism and hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_5959', 'tradeNames_string': 'Delatestryl, Primoteston depot, Testosterone enanthate, Xyosted (autoinjector)', 'drugName': 'Testosterone Enanthate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Androgen Receptor agonist', 'linkedDiseasesDrug_... | general | Similarity Search, Select | Metadata |
Q22.610 | Q22 | What is Talzenna? | Talzenna, also known generically as Talazoparib Tosylate, was approved by the FDA in 2018 to treat breast carcinoma, breast neoplasm, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2224', 'tradeNames_string': 'Talzenna', 'drugName': 'Talazoparib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Poly [ADP-ribose] polymerase-1 inhibitor', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Breast Cancer ... | general | Similarity Search, Select | Metadata |
Q22.366 | Q22 | What is Levolet? | Levolet, also known generically as Levothyroxine Sodium, was approved by the FDA in 2000 to treat thyroid carcinoma, hypothyroidism, differentiated thyroid carcinoma, thyroid cancer, and congenital hypothyroidism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_5964', 'tradeNames_string': 'Eltroxin, Ermeza, Euthyrox, Evotrox, L-thyroxine henning, Levo-t, Levolet, Levothroid, Levothyroid, Levothyroxine sodium, Levoxine, Levoxyl, Novothyrox, Soloxine, Synthroid, Thyquidity, Thyro-tabs, Thyrol L, Thyroxine, Tirosint, Tirosint-sol, Unithroid', 'drugN... | general | Similarity Search, Select | Metadata |
Q22.344 | Q22 | What is Revlimid? | Revlimid, also known generically as Lenalidomide, was approved by the FDA in 2005 to treat myelodysplastic syndrome, immune system disease, multiple myeloma, anemia (phenotype), Mantle cell lymphoma, and anemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_456', 'tradeNames_string': 'Revlimid', 'drugName': 'Lenalidomide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'CRL4(CRBN) E3 ubiquitin ligase inhibitor', 'linkedDiseasesDrug_string': "Autism (EFO_0003758), Multiple Myeloma (EFO_0001378), ... | general | Similarity Search, Select | Metadata |
Q22.675 | Q22 | What is Ukoniq? | Ukoniq, also known generically as Umbralisib Tosylate, was approved by the FDA in 2021 to treat marginal zone B-cell lymphoma and follicular lymphoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_3011', 'tradeNames_string': 'Ukoniq', 'drugName': 'Umbralisib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Casein kinase I epsilon inhibitor', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Rectum Cancer (EFO_... | general | Similarity Search, Select | Metadata |
Q22.294 | Q22 | What is Zoladex? | Zoladex, also known generically as Goserelin, was approved by the FDA in 1989 to treat neoplasm. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_246', 'tradeNames_string': 'Novgos, Zoladex, Zoladex la', 'drugName': 'Goserelin Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor agonist', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315),... | general | Similarity Search, Select | Metadata |
Q22.288 | Q22 | What is Gvoke Hypopen? | Gvoke Hypopen, also known generically as Glucagon, was approved by the FDA in 1998 to treat Hypoglycemia and diabetes mellitus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_1857', 'tradeNames_string': 'Baqsimi, Glucagen Hypokit, Glucagon, Glucagon Emergency Kit, Gvoke hypopen, Gvoke pfs', 'drugName': 'Glucagon', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon receptor agonist', 'linkedDiseasesDrug_string': 'Diab... | general | Similarity Search, Select | Metadata |
Q22.337 | Q22 | What is Prevacid Iv? | Prevacid Iv, also known generically as Lansoprazole, was approved by the FDA in 1995 to treat Peptic ulcer, gastroesophageal reflux disease, and gastric ulcer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2720', 'tradeNames_string': 'Lansoprazole, Opiren, Prevacid, Prevacid 24 hr, Prevacid Delayed Release, Prevacid Solutab, Prevacid iv, Zoton', 'drugName': 'Lansoprazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Potassium-transporting A... | general | Similarity Search, Select | Metadata |
Q22.484 | Q22 | What is Oxtellar Xr? | Oxtellar Xr, also known generically as Oxcarbazepine, was approved by the FDA in 2000 to treat Seizure and epilepsy. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_1913', 'tradeNames_string': 'Oxcarbazepine, Oxtellar xr, Trileptal', 'drugName': 'Oxcarbazepine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Aggre... | general | Similarity Search, Select | Metadata |
Q22.55 | Q22 | What is Qulipta? | Qulipta, also known generically as Atogepant, was approved by the FDA in 2021 to treat migraine disorder. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2683', 'tradeNames_string': 'Qulipta', 'drugName': 'Atogepant', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Calcitonin gene-related peptide type 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'n... | general | Similarity Search, Select | Metadata |
Q22.252 | Q22 | What is Fenoglide? | Fenoglide, also known generically as Fenofibrate, was approved by the FDA in 1993 to treat Abnormal circulating lipid concentration, Hypercholesterolemia, cardiovascular disease, diabetes mellitus, hypothyroidism, and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_1497', 'tradeNames_string': 'Antara, Antara (micronized), Fenofibrate, Fenofibrate (micronized), Fenogal, Fenoglide, Lipantil, Lipantil micro 200, Lipantil micro 267, Lipantil micro 67, Lipidil, Lipofen, Supralip 160, Tricor, Tricor (micronized), Triglide', 'drugName': 'Fenofibrate', 'drug... | general | Similarity Search, Select | Metadata |
Q22.227 | Q22 | What is Balversa? | Balversa, also known generically as Erdafitinib, was approved by the FDA in 2019 to treat bladder tumor, cancer, neoplasm, urothelial carcinoma, and urinary bladder cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_5765', 'tradeNames_string': 'Balversa', 'drugName': 'Erdafitinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_00013... | general | Similarity Search, Select | Metadata |
Q22.136 | Q22 | What is Trilipix? | Trilipix, also known generically as Choline Fenofibrate, was approved by the FDA in 2008 to treat cardiovascular disease. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_347', 'tradeNames_string': 'Fenocor-67, Fenogal, Fibricor, Lipanthyl, Lipofen, Lofibra, Supralip, Trilipix', 'drugName': 'Fenofibric Acid', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Peroxisome proliferator-activated receptor alpha agonist... | general | Similarity Search, Select | Metadata |
Q22.647 | Q22 | What is Xeljanz? | Xeljanz, also known generically as Tofacitinib Citrate, was approved by the FDA in 2012 to treat rheumatoid arthritis and psoriatic arthritis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_3515', 'tradeNames_string': 'Xeljanz, Xeljanz xr', 'drugName': 'Tofacitinib Citrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Janus Kinase (JAK) inhibitor', 'linkedDiseasesDrug_string': 'Discoid Lupus Erythematosus (MONDO_0019558), At... | general | Similarity Search, Select | Metadata |
Q22.139 | Q22 | What is Zetonna? | Zetonna, also known generically as Ciclesonide, was approved by the FDA in 2006 to treat Nasal congestion, Airway obstruction, seasonal allergic rhinitis, allergic rhinitis, Rhinitis, Allergic, Perennial, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_4432', 'tradeNames_string': 'Alvesco, Alvesco 160, Alvesco 80, Omnaris, Zetonna', 'drugName': 'Ciclesonide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979),... | general | Similarity Search, Select | Metadata |
Q22.112 | Q22 | What is Cabometyx? | Cabometyx, also known generically as Cabozantinib, was approved by the FDA in 2012 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_3579', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib S-Malate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075... | general | Similarity Search, Select | Metadata |
Q22.184 | Q22 | What is Pristiq? | Pristiq, also known generically as Desvenlafaxine, was approved by the FDA in 2008 to treat unipolar depression, major depressive disorder, and depressive disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_1437', 'tradeNames_string': 'Desvenlafaxine, Khedezla, Pristiq', 'drugName': 'Desvenlafaxine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_00037... | general | Similarity Search, Select | Metadata |
Q22.438 | Q22 | What is Morphabond Er? | Morphabond Er, also known generically as Morphine Sulfate, was approved by the FDA in 1984 to treat Chronic pain, cancer, pain, and drug dependence. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_3650', 'tradeNames_string': 'Arymo er, Astramorph pf, Avinza, Depodur, Duramorph, Duramorph pf, Duromorph, Filnarine sr, Infumorph, Kadian, Moraxen, Morcap sr, Morphabond, Morphabond er, Morphgesic sr, Morphine sulfate, Morphine sulfate (autoinjector), Ms contin, Mst continus, Oramorph, Or... | general | Similarity Search, Select | Metadata |
Q22.561 | Q22 | What is Naropin? | Naropin, also known generically as Ropivacaine Hydrochloride, was approved by the FDA in 1996 to treat pain. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_4841', 'tradeNames_string': 'Narapin, Naropin, Ropivacaine hydrochloride', 'drugName': 'Ropivacaine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Head And Ne... | general | Similarity Search, Select | Metadata |
Q22.489 | Q22 | What is Oxycontin? | Oxycontin, also known generically as Oxycodone Hydrochloride, was approved by the FDA in 1950 to treat Chronic pain and pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_6046', 'tradeNames_string': 'Oxycontin, Proladone, Xtampza er', 'drugName': 'Oxycodone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Cancer (MONDO_0004992),... | general | Similarity Search, Select | Metadata |
Q22.523 | Q22 | What is Livalo? | Livalo, also known generically as Pitavastatin Calcium, was approved by the FDA in 2009 to treat Abnormal circulating lipid concentration and hyperlipidemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_763', 'tradeNames_string': 'Livalo, Pitavastatin calcium', 'drugName': 'Pitavastatin Calcium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'HMG-CoA reductase inhibitor', 'linkedDiseasesDrug_string': 'Abnormal Circulating Lipid Concentratio... | general | Similarity Search, Select | Metadata |
Q22.135 | Q22 | What is Clorotekal? | Clorotekal, also known generically as Chloroprocaine Hydrochloride, was approved by the FDA in 1955. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2193', 'tradeNames_string': 'Ampres, Chloroprocaine hydrochloride, Clorotekal, Nesacaine, Nesacaine-mpf', 'drugName': 'Chloroprocaine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linked... | general | Similarity Search, Select | Metadata |
Q22.179 | Q22 | What is Firmagon? | Firmagon, also known generically as Degarelix Acetate, was approved by the FDA in 2008 to treat prostate adenocarcinoma and prostate carcinoma. It is a protein therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_6054', 'tradeNames_string': 'Firmagon', 'drugName': 'Degarelix Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor antagonist', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Prostate Ca... | general | Similarity Search, Select | Metadata |
Q22.73 | Q22 | What is Qnasl? | Qnasl, also known generically as Beclomethasone Dipropionate, was approved by the FDA in 1976 to treat Nasal congestion, Airway obstruction, seasonal allergic rhinitis, allergic rhinitis, Rhinitis, Allergic, Perennial, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_5013', 'tradeNames_string': 'Aerobec 100, Aerobec 50, Aerobec fte 250, Asmabec clickhaler, Asmabec spacehaler, Beclazone 100, Beclazone 100 e-breathe, Beclazone 200, Beclazone 250, Beclazone 250 e-breathe, Beclazone 50, Beclazone 50 e-breathe, Becloaqua 50, Becloforte, Becloforte e-breathe... | general | Similarity Search, Select | Metadata |
Q22.258 | Q22 | What is Subsys? | Subsys, also known generically as Fentanyl, was approved by the FDA in 1968 to treat Chronic pain, cancer, neoplasm, pain, and migraine disorder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_6302', 'tradeNames_string': 'Abstral, Actiq, Breakyl, Duragesic, Duragesic-100, Duragesic-12, Duragesic-25, Duragesic-37, Duragesic-50, Duragesic-75, Durogesic, Durogesic dtrans, Effentora, Fencino, Fentalis reservoir, Fentanyl-100, Fentanyl-12, Fentanyl-25, Fentanyl-37, Fentanyl-50, Fenta... | general | Similarity Search, Select | Metadata |
Q22.584 | Q22 | What is Januvia? | Januvia, also known generically as Sitagliptin, was approved by the FDA in 2006 to treat diabetes mellitus. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2411', 'tradeNames_string': 'Janumet Xr, Januvia', 'drugName': 'Sitagliptin Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dipeptidyl peptidase IV inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperli... | general | Similarity Search, Select | Metadata |
Q22.656 | Q22 | What is Conzip? | Conzip, also known generically as Tramadol Hydrochloride, was approved by the FDA in 1995 to treat Chronic pain, pain, and drug dependence. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_3268', 'tradeNames_string': 'Aceon, Conzip, Dromadol sr, Dromadol xl, Invodol sr, Larapam sr, Mabron, Maneo, Marol, Maxitram sr, Nobligan ret, Oldaram, Qdolo, Rybix odt, Ryzolt, Tilodol sr, Tradorec xl, Tramacet, Tramadol hydrochloride, Tramake, Tramake insts, Tramquel sr, Tramulief sr, Ul... | general | Similarity Search, Select | Metadata |
Q22.602 | Q22 | What is Zembrace Symtouch? | Zembrace Symtouch, also known generically as Sumatriptan Succinate, was approved by the FDA in 1992 to treat migraine disorder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_1609', 'tradeNames_string': 'Alsuma, Imigran, Imigran 50, Imigran radis, Imigran recovery, Imigran subject, Imitrex, Imitrex statdose, Migraitan, Migraleve ultra, Onzetra xsail, Sumatriptan succinate, Sumavel dosepro, Zecuity, Zembrace symtouch', 'drugName': 'Sumatriptan Succinate', 'drugM... | general | Similarity Search, Select | Metadata |
Q22.673 | Q22 | What is Tukysa? | Tukysa, also known generically as Tucatinib, was approved by the FDA in 2020 to treat breast carcinoma, cancer, neoplasm, brain neoplasm, HER2 Positive Breast Carcinoma, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_5133', 'tradeNames_string': 'Tukysa', 'drugName': 'Tucatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-2 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Hepatocellular Carcinoma ... | general | Similarity Search, Select | Metadata |
Q22.358 | Q22 | What is Recorlev? | Recorlev, also known generically as Levoketoconazole, was approved by the FDA in 2021 to treat Cushing syndrome and adrenal gland hyperfunction. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_3929', 'tradeNames_string': 'Extina, Ketosidin, Ketozole, Nizoral, Nizoral A-D, Panfungol, Recorlev, Xolegel', 'drugName': 'Levoketoconazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cytochrome P450 11B1 inhibitor', 'linkedDiseasesDru... | general | Similarity Search, Select | Metadata |
Q22.77 | Q22 | What is Beleodaq? | Beleodaq, also known generically as Belinostat, was approved by the FDA in 2014 to treat unspecified peripheral T-cell lymphoma, cancer, neoplasm, mature T-cell and NK-cell non-Hodgkin lymphoma, and T-cell non-Hodgkin lymphoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_1601', 'tradeNames_string': 'Beleodaq', 'drugName': 'Belinostat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Histone deacetylase inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgki... | general | Similarity Search, Select | Metadata |
Q22.151 | Q22 | What is Cotellic? | Cotellic, also known generically as Cobimetinib, was approved by the FDA in 2015 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_3656', 'tradeNames_string': 'Cotellic', 'drugName': 'Cobimetinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dual specificity mitogen-activated protein kinase kinase 1 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Mu... | general | Similarity Search, Select | Metadata |
Q22.352 | Q22 | What is Elepsia Xr? | Elepsia Xr, also known generically as Levetiracetam, was approved by the FDA in 1999 to treat Seizure, Bilateral tonic-clonic seizure, Focal-onset seizure, epilepsy, and epilepsy with generalized tonic-clonic seizures. It is a small molecule therapy that acts as a(n) modulator and blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_283', 'tradeNames_string': 'Desitrend, Elepsia xr, Keppra, Keppra xr, Levetiracetam, Levetiracetam in sodium chloride, Matever, Spritam', 'drugName': 'Levetiracetam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Synaptic vesicle glycoprote... | general | Similarity Search, Select | Metadata |
Q22.93 | Q22 | What is Vyleesi (Autoinjector)? | Vyleesi (Autoinjector), also known generically as Bremelanotide Acetate, was approved by the FDA in 2019 to treat mental or behavioural disorder and sexual dysfunction. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_177', 'tradeNames_string': 'Vyleesi (autoinjector)', 'drugName': 'Bremelanotide Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Melanocortin receptor 4 agonist', 'linkedDiseasesDrug_string': 'Sexual Dysfunction (EFO_0004714), Mental Or Behav... | general | Similarity Search, Select | Metadata |
Q22.688 | Q22 | What is Gemtesa? | Gemtesa, also known generically as Vibegron, was approved by the FDA in 2020 to treat Urinary incontinence, urgency urinary incontinence, and overactive bladder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_9', 'tradeNames_string': 'Gemtesa', 'drugName': 'Vibegron', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-3 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Overactive Bladder (EFO_1... | general | Similarity Search, Select | Metadata |
Q22.11 | Q22 | What is Gilotrif? | Gilotrif, also known generically as Afatinib Dimaleate, was approved by the FDA in 2013 to treat non-small cell lung carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_1042', 'tradeNames_string': 'Gilotrif, Giotrif', 'drugName': 'Afatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Epidermal growth factor receptor erbB1 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma... | general | Similarity Search, Select | Metadata |
Q22.64 | Q22 | What is Children'S Astepro Allergy? | Children'S Astepro Allergy, also known generically as Azelastine Hydrochloride, was approved by the FDA in 1996 to treat Nasal congestion, seasonal allergic rhinitis, allergic rhinitis, allergic conjunctivitis, vasomotor rhinitis, and Rhinitis, Allergic, Perennial. It is a small molecule therapy that acts as a(n) antag... | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_3567', 'tradeNames_string': "Astelin, Astepro, Astepro allergy, Azelastine hydrochloride, Children's astepro allergy, Optilast, Optivar, Rhinolast, Rhinolast allergy", 'drugName': 'Azelastine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechan... | general | Similarity Search, Select | Metadata |
Q22.642 | Q22 | What is Klisyri? | Klisyri, also known generically as Tirbanibulin, was approved by the FDA in 2020 to treat actinic keratosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_5805', 'tradeNames_string': 'Klisyri', 'drugName': 'Tirbanibulin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase SRC inhibitor', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Prostate Cancer (MO... | general | Similarity Search, Select | Metadata |
Q22.663 | Q22 | What is Desyrel? | Desyrel, also known generically as Trazodone Hydrochloride, was approved by the FDA in 1981 to treat unipolar depression, major depressive disorder, and depressive disorder. It is a small molecule therapy that acts as a(n) inhibitor and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_4975', 'tradeNames_string': 'Desyrel, Molipaxin, Molipaxin cr, Oleptro, Trazodone hydrochloride, Trialodine', 'drugName': 'Trazodone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', ... | general | Similarity Search, Select | Metadata |
Q22.177 | Q22 | What is Defitelio? | Defitelio, also known generically as Defibrotide Sodium, was approved by the FDA in 2016 to treat hepatic veno-occlusive disease. It is a oligonucleotide therapy that acts as a(n) activator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_826', 'tradeNames_string': 'Defitelio', 'drugName': 'Defibrotide Sodium', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'activator', 'drugMechanismOfAction': 'Plasminogen activator', 'linkedDiseasesDrug_string': 'Hepatic Veno-Occlusive Disease (MONDO_0019514)', 'newLinkedTarget... | general | Similarity Search, Select | Metadata |
Q22.260 | Q22 | What is Lazanda? | Lazanda, also known generically as Fentanyl Citrate, was approved by the FDA in 1968 to treat cancer and pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_733', 'tradeNames_string': 'Abstral, Actiq, Fentanyl, Fentanyl citrate, Fentanyl citrate preservative free, Fentora, Lazanda, Onsolis, Sublimaze, Sublimaze preservative free, Thalamonal', 'drugName': 'Fentanyl Citrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'd... | general | Similarity Search, Select | Metadata |
Q22.674 | Q22 | What is Ubrelvy? | Ubrelvy, also known generically as Ubrogepant, was approved by the FDA in 2019 to treat migraine disorder. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_528', 'tradeNames_string': 'Ubrelvy', 'drugName': 'Ubrogepant', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Calcitonin gene-related peptide type 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'n... | general | Similarity Search, Select | Metadata |
Q22.32 | Q22 | What is Nexterone? | Nexterone, also known generically as Amiodarone Hydrochloride, was approved by the FDA in 1985 to treat Ventricular arrhythmia, ventricular fibrillation, and ventricular tachycardia. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_3146', 'tradeNames_string': 'Amidox, Amiodarone hydrochloride, Amyben, Cordarone, Cordarone x, Cordarone x 100, Cordarone x 200, Darmil, Nexterone, Pacerone', 'drugName': 'Amiodarone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction'... | general | Similarity Search, Select | Metadata |
Q22.375 | Q22 | What is Linzess? | Linzess, also known generically as Linaclotide, was approved by the FDA in 2012 to treat Constipation, irritable bowel syndrome, and constipation disorder. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_5063', 'tradeNames_string': 'Constella, Linzess', 'drugName': 'Linaclotide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Heat-stable enterotoxin receptor agonist', 'linkedDiseasesDrug_string': 'Colorectal Adenoma (EFO_0005406), Constipation (HP_00... | general | Similarity Search, Select | Metadata |
Q22.577 | Q22 | What is Ozempic? | Ozempic, also known generically as Semaglutide, was approved by the FDA in 2017 to treat diabetes mellitus and type 2 diabetes mellitus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_6086', 'tradeNames_string': 'Ozempic, Rybelsus, Wegovy', 'drugName': 'Semaglutide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon-like peptide 1 receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Osteopenia (H... | general | Similarity Search, Select | Metadata |
Q22.79 | Q22 | What is Welireg? | Welireg, also known generically as Belzutifan, was approved by the FDA in 2021 to treat clear cell renal carcinoma, neoplasm, renal cell carcinoma, pancreatic neuroendocrine tumor, von Hippel-Lindau disease, and hemangioblastoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_342', 'tradeNames_string': 'Welireg', 'drugName': 'Belzutifan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Endothelial PAS domain-containing protein 1 inhibitor', 'linkedDiseasesDrug_string': 'Hemangioblastoma (MONDO_0016748), Chronic Ki... | general | Similarity Search, Select | Metadata |
Q22.539 | Q22 | What is Doral? | Doral, also known generically as Quazepam, was approved by the FDA in 1985 to treat insomnia. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_4794', 'tradeNames_string': '', 'drugName': 'Avdoralimab', 'drugMolecularType': 'Antibody', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'C5a anaphylatoxin chemotactic receptor inhibitor', 'linkedDiseasesDrug_string': 'Covid-19 (MONDO_0100096), Bullous Pemphigoid (EFO_0007187), ... | general | Similarity Search, Select | Metadata |
Q22.555 | Q22 | What is Atelvia? | Atelvia, also known generically as Risedronate Sodium, was approved by the FDA in 1998 to treat postmenopausal osteoporosis, osteoporosis, and Paget disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_4717', 'tradeNames_string': 'Actonel, Atelvia, Risedronate sodium', 'drugName': 'Risedronate Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Farnesyl diphosphate synthase inhibitor', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_00... | general | Similarity Search, Select | Metadata |
Q22.215 | Q22 | What is Promacta? | Promacta, also known generically as Eltrombopag Olamine, was approved by the FDA in 2008 to treat Thrombocytopenia, chronic hepatitis C virus infection, severe aplastic anemia, and autoimmune thrombocytopenic purpura. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_2769', 'tradeNames_string': 'Promacta, Promacta kit', 'drugName': 'Eltrombopag Olamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thrombopoietin receptor agonist', 'linkedDiseasesDrug_string': 'Thrombocytopenia (HP_0001873), Autoimmune T... | general | Similarity Search, Select | Metadata |
Q22.56 | Q22 | What is Tavneos? | Tavneos, also known generically as Avacopan, was approved by the FDA in 2021 to treat anti-neutrophil antibody associated vasculitis, Granulomatosis with Polyangiitis, microscopic polyangiitis, and Anti-neutrophil cytoplasmic antibody-associated vasculitis. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_5921', 'tradeNames_string': 'Tavneos', 'drugName': 'Avacopan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'C5a anaphylatoxin chemotactic receptor antagonist', 'linkedDiseasesDrug_string': 'Microscopic Polyangiitis (EFO_1000784), Atypical... | general | Similarity Search, Select | Metadata |
Q22.138 | Q22 | What is Omnaris? | Omnaris, also known generically as Ciclesonide, was approved by the FDA in 2006 to treat Nasal congestion, Airway obstruction, seasonal allergic rhinitis, allergic rhinitis, Rhinitis, Allergic, Perennial, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) ... | [{'UUID': 'DrugGeneTargets_v2_4432', 'tradeNames_string': 'Alvesco, Alvesco 160, Alvesco 80, Omnaris, Zetonna', 'drugName': 'Ciclesonide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979),... | general | Similarity Search, Select | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.